DefiniGEN strengthens board with ex-chief executive of MRC
Sir John Savill, formerly chief executive of the Medical Research Council in the UK, has become a non-executive director of Cambridge life science company DefiniGEN.
DefiniGEN is regarded as a world leader in human iPSC differentiation and disease modelling.
Sir John brings his expertise in translational science to DefiniGEN enabling the company to accelerate the development of new products and services which can improve the efficiency and economics of drug development.
Within his role at MRC, he was responsible to UK Parliament for expenditure of approximately £800 million per year as MRC’s accounting officer. Alongside the MRC role, Sir John was also vice-principal and head of the College of Medicine at the University of Edinburgh.
As a renowned expert in research and innovation, Sir John will aid DefiniGEN in further developing its partnerships with the pharmaceutical and biomedical communities.
Dr Marcus Yeo, DefiniGEN’s CEO, said: “With his extensive experience as a highly-regarded clinician and scientist I am confident that Sir John will prove to be highly valuable as DefiniGEN continues to grow internationally in key markets.”
Sir John Savill added: “DefiniGEN is one of the UK’s most innovative translational science companies providing valuable tools for biomedical research. I’m delighted to join the board at this important stage in the company’s development.”